Concomitant Deep Venous Thrombosis Research Articles

FRI111 Venous Thromboembolism In Cushing Syndrome - A Call For Standardized Anticoagulation Regimen In Hypercortisolism

Abstract Disclosure: M. Minasyan: None. A. Bryk-Wiazania: None. E. Rzepka: None. A. Bogusławska: None. A. Hubalewska-Dydejczyk: None. A. Gilis-Januszewska: None. Venous thromboembolism in Cushing Syndrome - a call for standardized anticoagulation regimen in hypercortisolism. Cushing Syndrome (CS) is associated with a 18-fold higher risk of venous thromboembolism (VTE) when compared to the general population with the similar demographic characteristics. Despite numerous studies on hypercoagulability in CS, the unequivocal recommendations regarding timing and dosing of thromboprophylaxis in hypercortisolism are still lacking. We present a case series of patients with CS and VTE, hospitalized in the Endocrinology Department of University Hospital in Krakow. Among 135 patients with CS, we found 7cases of VTE (5.19%), aged 35-65 years, mostly females (n=6). The etiology of CS was predominately pituitary (n=3), the other tissue origins of CS were: adrenal (n=2), ectopic(n=1) and adrenal carcinoma (n=1). Pulmonary embolism (PE) was found in 3 patients, deep venous thrombosis (DVT) in 2 patients, while 2 patients suffered from concomitant DVT and PE. We found that one patient had VTE 5 months before inducing the biochemical remission by a transsphenoidal surgery, while 2 patients within the 30 days after inducing the biochemical remission by either a transsphenoidal surgery in one, or metyrapone treatment in 2nd case. In the remaining 4 patients, VTE episode preceded the diagnosis of CS, ranging from 1 year to 2 months prior to the diagnosis. Among them, 2 PE episodes were associated with other predisposing factors, such as (1) postpartum PE in a 36-year-old women, who was subsequently diagnosed with Cushing disease, and (2) combined oral contraceptive in a 35-year-old woman, who suffered from the peripheral PE, and was eventually diagnosed with adrenal CS. Of note, at the time of VTE episode, 1 patient was treated with warfarin (international normalized ratio at the time of VTE, 1.66), another one took apixaban. One fatal PE occurred on the thromboprophylaxis with low molecular weight heparin, in the hypocortisolemia following metyrapone implementation. To summarize, VTE episode: 1. may be the first, life-threatening presentation of CS; 2. may occur after treatment of hypercortisolism; 3. may happen in patients on thromboprophylaxis or anticoagulant treatment; 4. should be included in the differential diagnosis of a thrombotic event despite coexisting transient factor (e.g. oral contraceptive, delivery). 5. Further multicenter studies are essential to understand the hypercoagulability in CS, and to create the recommendations on this topic. Presentation: Friday, June 16, 2023

Superficial Venous Thrombosis with Concomitant Deep Venous Thrombosis of Upper Extremity, A Case Report

Superficial Venous Thrombosis with Concomitant Deep Venous Thrombosis of Upper Extremity, A Case Report

Concomitant thrombosis in patients with cellulitis as incidental finding.

Although inflammation and thrombosis are tightly connected, only 45% of patients with lower leg cellulitis receive anticoagulant therapy. Available data about the prevalence of concomitant deep venous thrombosis (DVT) in patients with cellulitis of the lower extremity is scarce and general guidelines regarding diagnosis and prevention of venous thromboembolism are missing. We sought to determine how frequently DVT occurs as an incidental finding in patients with cellulitis and to provide recommendations for diagnostics and anticoagulant therapy. Patients' records were analysed and 192 consecutive patients with cellulitis were included in this study. The prevalence of concomitant DVT was examined by duplex ultrasound, as well as comorbidities and risk factors. We detected thrombosis in 12.0% of the patients with lower leg cellulitis, of which 43.5% were located in a proximal vein and 52.2% in the veins of the calf. Our results clearly indicate that cellulitis is not only a differential diagnosis, but should be considered a risk factor for venous thrombosis. Therefore, prophylactic anticoagulation should be considered in patients suffering from cellulitis and a systematic screening for venous thrombosis in patients with cellulitis should be performed.

Venous thromboembolism in lung transplant recipients real world experience from a high volume center

Venous thromboembolism (VTE) post lung transplantation is common and has been associated with worse post transplant survival. We report a comprehensive single center review of VTE incidence in the first post transplant year, investigate modifiable risk factors and assess impact on short term outcomes. Retrospective review of all lung transplant recipients between August 2016 to 2018 at Temple University Hospital. Patients were followed for 1 year post transplant. All patients were screened for deep venous thrombosis (DVT) within the first 2 weeks with a venous duplex study. Pre transplant, intra operative, post operative variables, and peri-operative practice patterns were compared between VTE positive and VTE negative groups. Logistic regression modeling was used to identify risk factors for early VTE (VTE within 30 days after transplant). A total of 235 patients were included in the study, 58 patients (24.7%) developed a VTE in the first post transplant year. Median time to diagnosis was 17 days. Of the patients with VTE, 76% had an isolated DVT, 13.5 % had an isolated pulmonary embolism (PE), and 10.3% had concomitant DVT and PE. In a multivariate logistic regression model, cardiopulmonary bypass (CPB) (OR 1.93 p=0.015) and interruption of VTE prophylaxis (OR 4.42 p < 0.0001) were predictive of early VTE. VTE post lung transplant is common despite the use of prophylactic anticoagulation. CPB use and interruption of DVT prophylaxis are risk factors for early post transplant VTE. Measures to ensure consistent and uninterrupted prophylaxis may help decrease VTE incidence after lung transplantation.

Impact of no, distal, and proximal deep vein thrombosis on clinical outcomes in patients with acute pulmonary embolism: From the COMMAND VTE registry

BackgroundThe majority of acute pulmonary embolism (PE) is caused by thrombus developed from leg veins. However, impact of concomitant deep venous thrombosis (DVT) on clinical outcomes has not been fully evaluated in patients with acute PE. MethodsThe COMMAND VTE Registry is a multicenter registry enrolling consecutive 3027 patients with acute symptomatic venous thromboembolism (VTE) in Japan. The current study population consisted of 655 acute PE patients who underwent lower extremities ultrasound examination at diagnosis for the assessment of concomitant DVT status. ResultsThere were 424 patients with proximal DVT (64.7%), 162 patients with distal DVT (24.7%), and 69 patients with no DVT (10.5%). The cumulative 90-day incidence of all-cause death was higher in proximal DVT patients than in distal DVT and no DVT patients (7.9%, 2.5%, and 1.4%, p = 0.01). Regarding the causes of death, the cumulative 90-day incidence of PE-related death was low, and not significantly different across the 3 groups (1.4%, 0.6%, and 1.7%, p = 0.62). The most frequent cause of death was cancer in proximal and distal DVT patients. There were no significant differences in 90-day rates of recurrent VTE and major bleeding, regardless of the status of concomitant DVT (2.9%, 3.2%, and 2.2%, p = 0.79, and 1.5%, 4.4%, and 4.9%, p = 0.46, respectively). ConclusionsAcute PE with proximal DVT at diagnosis was associated with a higher risk for short-term mortality than in patients without DVT, while the risk for short-term mortality was not significantly different between distal DVT patients and patients without DVT.

Impact of concomitant deep or superficial venous thrombosis of the legs on survival of patients with pulmonary embolism

BackgroundPulmonary embolism (PE) is a frequent cause of death and morbidity. A few studies suggest that clot burden in pulmonary artery bed is related to PE patients' survival, but the impact of concomitant deep venous thrombosis and/or thrombophlebitis (DVT) on short-term survival of PE patients remains unclear. Thus, we aimed to investigate the impact of DVT on adverse outcomes in PE patients. MethodsPatients of the nationwide inpatient sample with PE (ICD-code I26) were stratified for DVT (ICD-code I80) and compared for patient characteristics, risk stratification markers, treatments and outcomes. Impact of concomitant DVT on adverse in-hospital outcomes was tested. ResultsOverall, 346,586 PE patients (53.3% females) were included in this analysis. Among these, in 126,477 (36.5%) DVT was coded. PE patients with DVT were younger, less often of female sex and VTE risk-factors (surgery, cancer) as well as cardiovascular and pulmonary diseases were less prevalent compared with isolated PE.PE patients with DVT showed a significant better survival (5.4% vs. 20.2%, P < .001) and lower adverse in-hospital event rate (9.7% vs. 27.4%, P < .001) compared to patients with isolated PE. Lower risk for in-hospital mortality (OR 0.238 [95%CI 0.232–0.245], P < .001) and adverse in-hospital events (OR 0.302 [95%CI 0.295–0.309], P < .001) were respectively independent of age, gender, comorbidities and reperfusion-treatments. ConclusionsConcomitant DVT affects survival of PE patients. Patients with an isolated PE had higher rate of in-hospital mortality and adverse in-hospital events. Our data suggest, that peripheral thrombus burden in PE with concomitant DVT might be less harmful in comparison to isolated PE with a probably larger thrombus burden.

Can Subfascial Endoscopic Perforator Surgery (SEPS) be Standard of Care in Advanced Chronic Venous Insufficiency (CVI)?

Subfascial Endoscopic Perforator Surgery (SEPS) is a minimally invasive technique to treat incompetent perforating veins. Thirty patients with advanced chronic venous insufficiency (CVI) belonging to CEAP clinical class C4–C6 with incompetent perforating veins in the leg and competent sapheno — femoral junction (SFJ) were subjected to SEPS. Patients with concomitant arterial disease and deep venous thrombosis (DVT) were excluded. Outcomes were evaluated after surgery up to 12 weeks. Out of 12 patients with active ulcer, complete healing was seen in 11 (92%) while one patient had partial healing at the end of 12 weeks. Wound dehiscence occurred in one patient (3.33%). On Doppler ultrasound at 12 weeks, postoperative persistence of perforators was seen in three patients (10%). Post-operatively, patients had minimal pain, negligible wound complications, short hospital stay, early return to normal activities and excellent ulcer healing. However, no significant improvement in skin changes was seen. SEPS can easily be considered as standard of care in advanced CVI.

A review on superficial venous thrombosis of the lower extremities

Superficial venous thrombosis of the lower extremity is a common medical condition worldwide. Most of its epidemiologic data have come from the Western hemisphere suggesting female predominance and a high risk of venous thromboembolism. Initial diagnosis is still based on clinical suspicion and physical findings, but duplex ultrasound is often required to rule out concomitant deep venous thrombosis. Management options, including surgical and medical means, have been attempted with inconsistent result. In the last decade, clinical trials using anticoagulants such as low molecular weight heparin and new oral anti-Xa anticoagulants have demonstrated beneficial effects. Currently, oral nonsteroidal anti-inflammatories with or without compression are still the predominant initial treatment despite the proven clinical efficacy of oral anticoagulation in lowering thrombotic risk and symptom relief. In this review, most of the studies analyzed are after the year 2010 through PubMed index search and thus making it a contemporary update.

Value of thrombolytic therapy for submassive pulmonary embolism patients

Background and aim of the study The aim of this study was to assess the value of streptokinase in patients with submassive pulmonary embolism (PE) due to unavailability of tissue plasminogen activator in our locality due to limited income sources. Patients and methods A prospective randomized controlled trial was conducted on a total number of 52 patients with a confirmed diagnosis of submassive PE confirmed by computed tomographic pulmonary angiography were further investigated by echocardiography and cardiac biomarkers after ethical approval from the IRB and confirmed written consent from the patients or first-degree relative. The study was conducted between January 2017 and December 2017, at the Chest Department, Mansoura University Hospitals, and the Cardiology Department, Specialized Internal Medicine Hospital, Faculty of Medicine, Mansoura University. Results Fifty-two patients who were diagnosed as having submassive PE were enrolled; 24 patients were randomized to the thrombolytic group (TG) and 28 to the anticoagulant group (AG) by simple randomization through opening a closed envelope. The two groups were compared as regards demographic data, pulmonary artery systolic pressure (PASP), presence of comorbidities (diabetes mellitus) and presence of malignancy or concomitant deep venous thrombosis as risk factors, and the incidence of unprovoked PE without any statistically significant results.The PASP measured 72 h after therapy in the TG was improved with statistically significant difference when compared with that measured before starting therapy (P Conclusion Thrombolytic therapy should be considered over anticoagulation as first-line management in submassive PE causing right ventricular dysfunction without hypotension. Clinical implications Early identification of submassive PE and start of thrombolytic therapy after exclusion of bleeding risk in the patient for thrombolysis can improve outcome and decrease hospital stay.

Risk of Pulmonary Embolism in Patients With Isolated Great Saphenous Vein Thrombus.

Risks associated with isolated great saphenous vein (GSV) thrombosis remain controversial. The purpose of this study is to identify the risk of pulmonary embolism (PE) in patients with isolated GSV thrombosis, particularly those with thrombus within 3 cm of the sapheno-femoral junction. A retrospective chart review of color flow Doppler lower extremity venous ultrasound examinations from an academic hospital from 2011 to 2016 was conducted. Seventy-eight patients were identified as having acute thrombus in their GSV and were then further stratified based on the presence or absence of concomitant deep venous thrombosis (DVT). A control group of 49 patients who presented with leg swelling and were found to have a normal color flow Doppler examination was also identified. Patients without thrombus (n = 49), patients with isolated GSV thrombus (n = 29), and patients with GSV thrombus with concomitant DVT (n = 49) underwent full chart review to determine whether any patients developed PE. This was diagnosed specifically by computed tomography angiogram or ventilation/perfusion scan, within 60 days of initial diagnosis of lower extremity thrombus. In our analysis, there was no significant difference in the risk of PE in patients with isolated GSV thrombus compared with a control group of normal patients (3.5% vs 2.0%, P = 0.38). However, patients with GSV thrombus and concomitant DVT had a significantly increased risk of PE compared with patients with isolated GSV thrombus (26.5% vs 3.5%, P = 0.01). We found that the risk of PE in patients with isolated GSV thrombus is not significantly increased compared with a normal cohort.

Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism

The impact of residual pulmonary obstruction on the outcome of patients with pulmonary embolism is uncertain.We recruited 647 consecutive symptomatic patients with a first episode of pulmonary embolism, with or without concomitant deep venous thrombosis. They received conventional anticoagulation, were assessed for residual pulmonary obstruction through perfusion lung scanning after 6 months and then were followed up for up to 3 years. Recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension were assessed according to widely accepted criteria.Residual pulmonary obstruction was detected in 324 patients (50.1%, 95% CI 46.2-54.0%). Patients with residual pulmonary obstruction were more likely to be older and to have an unprovoked episode. After a 3-year follow-up, recurrent venous thromboembolism and/or chronic thromboembolic pulmonary hypertension developed in 34 out of the 324 patients (10.5%) with residual pulmonary obstruction and in 15 out of the 323 patients (4.6%) without residual pulmonary obstruction, leading to an adjusted hazard ratio of 2.26 (95% CI 1.23-4.16).Residual pulmonary obstruction, as detected with perfusion lung scanning at 6 months after a first episode of pulmonary embolism, is an independent predictor of recurrent venous thromboembolism and/or chronic thromboembolic pulmonary hypertension.

Deep Vein Thrombosis in Patients with Pulmonary Embolism: Prevalance, Clinical Significance and Outcome.

Purpose:Deep venous thrombosis (DVT) and pulmonary embolism (PE) are considered as similar disease entities representing different clinical manifestations. The objectives of this study were: 1) to determine the prevalence and outcome of DVT in patients with PE; 2) to identify additional risk factors for PE-related unfavorable outcome and 30-day all-cause mortality; and 3) to establish the clinical importance of screening for concomitant DVT.Materials and Methods:From January 2013 to December 2015, a total of 141 patients with confirmed PE were evaluated. The prevalence and outcome of DVT in patients with PE was determined. Furthermore, the potential risk factors for PE-related unfavorable outcome and 30-day all-cause mortality were also analyzed.Results:The prevalence of concomitant DVT was 45.4%. PE-related unfavorable outcome was observed in 21.9% of all concomitant DVT, with all-cause mortality of 21.9%. There was no significant relationship between the presence of concomitant DVT and the development of PE-related unfavorable outcome or all-cause mortality. Our results indicated that heart rate >100/min and peripheral oxygen saturation <90% were independent predictors for PE-related unfavorable outcome. Regarding all-cause mortality, active malignancy and hypotension or shock were significant risk factors.Conclusion:Our findings demonstrate that approximately half of patients with PE possess DVT. However, this study failed to establish any clinical significance of concomitant DVT for PE-related unfavorable outcome and all-cause mortality. Tachycardia and hypoxemia were identified as significant predictors for PE-related unfavorable outcome along with active malignancy and hypotension or shock as significant risk factors of all-cause mortality.

Management of the Incidental Pulmonary Embolism.

The incidental pulmonary embolism (PE) is being identified at an increasing rate because of use of MDCT and presents a management challenge because of a lack of prospective data. Most clinicians treat patients with proximal or segmental incidental PE in the same manner as patients with suspected PE. The treatment of subsegmental PE may be guided by an assessment of patient symptoms, risk factors for recurrent venous thrombosis, and concomitant deep venous thrombosis.

Isolated Great Saphenous Vein Thrombus Is Associated With High Rates of Propagation and Deep Venous Thrombosis Regardless of Treatment

Isolated great saphenous vein thrombus (GSVT) is generally regarded as benign, and treatment is heterogeneous. Complications include thrombus propagation, deep venous thrombosis (DVT), and symptom persistence. We reviewed demographics, comorbidities, treatments, and outcomes of isolated GSVT at our institution. Records of patients who had lower extremity venous duplex (LEVD) imaging that demonstrated GSVT without concomitant DVT between July 2008 and June 2014 were reviewed. Demographic, medical, treatment, outcomes, and follow-up LEVD data were collected. During the study period, 42,129 LEVD examinations were performed. Of 80 limbs with GSVT, 9 with ipsilateral DVT and 4 post-laser ablation were excluded, leaving 67 limbs from 61 patients for analysis. Mean clinical follow-up was 761 days. Of these patients, 14.9% had a hypercoagulable state and 31.3% had prior GSVT or DVT; 22.4% of patients had malignant disease, 19.4% had recent surgery, and 3% had recent trauma; 58.2% were inpatients, who on average had more comorbidities than outpatients. Regarding treatment, 28.4% of patients were observed, 13.4% were treated with aspirin or nonsteroidal anti-inflammatory drugs, and 58.2% were anticoagulated. Following treatment, 38.8% of limbs remained symptomatic; 29 patients (43.3%) had repeated LEVD imaging at a median follow-up of 2 days. In this group, five (17.2%) had GSVT propagation and six (20.7%) developed new DVT. Two of the five patients who had GSVT propagation and five of the six who developed new DVT had been anticoagulated since their initial LEVD examination. At initial LEVD imaging, 13 patients (44.8%) had thrombus within 5 cm of the saphenofemoral junction (SFJ) and 16 (55.2%) had thrombus >5 cm from the SFJ. Of the patients with thrombus within 5 cm of the SFJ, there was no GSVT propagation and DVT occurred in 2 (15.3%). Of the patients with thrombus >5 cm from the SFJ, five (31.2%) had GSVT propagation and DVT occurred in four (25%). Isolated GSVT tends to affect patients with hypercoagulable states, prior clotting, malignant disease, or recent surgery. Treatment is heterogeneous and symptom persistence is common. Thrombus propagation and DVT are seen often in patients who receive follow-up duplex ultrasound examination, regardless of treatment. Proximity of clot to the SFJ is not associated with increased risk of propagation or DVT.

“Saved by the Pacing Catheter”: Gigantic Right Atrial Thromboembolus as a Cause of Pulmonary Embolism

Pulmonary embolism (PE) related to the presence of right heart thromboemboli entails a higher mortality rate than PE alone. Furthermore, right heart thromboemboli are often associated with deep venous thrombosis. The most effective therapy for haemodynamically stable patients remains unknown, although recent data suggest that thrombolytic therapy is associated with a better outcome. We describe the case of an 83-year-old woman, hospitalized with PE consequent to right heart thrombus-in-transit, in whom investigation revealed a concomitant deep venous thrombosis. She required thrombolysis, given the high mortality risk that is traditionally associated with this clinical entity.

A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients

BackgroundThis study aims to determine the incidence of pulmonary embolism (PE) in trauma and orthopedic patients within a regional tertiary referral center and its association with the pattern of injury, type of treatment, co-morbidities, thromboprophylaxis and mortality.MethodsAll patients admitted to our institution between January 2010 and December 2011, for acute trauma or elective orthopedic procedures, were eligible to participate in this study. Our cohort was formed by identifying all patients with clinical features of PE who underwent Computed Tomography-Pulmonary Angiogram (CT-PA) to confirm or exclude the clinical suspicion of PE, within six months after the injury or the surgical procedure.Case notes and electronic databases were reviewed retrospectively to identify each patient’s venous thromboembolism (VTE) risk factors, type of treatment, thromboprophylaxis and mortality.ResultsOut of 18,151 patients admitted during the study period only 85 (0.47%) patients developed PE (positive CT-PA) (24 underwent elective surgery and 61 sustained acute trauma). Of these, only 76% of the patients received thromboprophylaxis. Hypertension, obesity and cardiovascular disease were the most commonly identifiable risk factors. In 39% of the cases, PE was diagnosed during the in-hospital stay. The median time of PE diagnosis, from the date of injury or the surgical intervention was 23 days (range 1 to 312). The overall mortality rate was 0.07% (13/18,151), but for those who developed PE it was 15.29% (13/85). Concomitant deep venous thrombosis (DVT) was identified in 33.3% of patients. The presence of two or more co-morbidities was significantly associated with the incidence of mortality (unadjusted odds ratio (OR) = 3.52, 95% confidence interval (CI) (1.34, 18.99), P = 0.034). Although there was also a similar clinical effect size for polytrauma injury on mortality (unadjusted OR = 1.90 (0.38, 9.54), P = 0.218), evidence was not statistically significant for this factor.ConclusionsThe incidence of VTE was comparable to previously reported rates, whereas the mortality rate was lower. Our local protocols that comply with the National Institute for Health and Clinical Excellence (NICE) guidelines in the UK appear to be effective in preventing VTE and reducing mortality in trauma and orthopedic patients.

Concomitant deep venous thrombosis, femoral artery thrombosis, and pulmonary embolism after air travel.

The association between air travel and deep venous thrombosis and/or pulmonary embolism “economy-class syndrome” is well described. However, this syndrome does not describe any association between long duration travel and arterial thrombosis or coexistence of venous and arterial thrombosis. We present a case of concomitant deep venous thrombosis, acute femoral artery thrombosis, and bilateral pulmonary embolisms in a patient following commercial air travel. Echocardiogram did not reveal an intracardiac shunt that may have contributed to the acute arterial occlusion from a paradoxical embolus. To our knowledge, this is the first report in the literature that associates air traveling with both arterial and venous thrombosis.

RANDOMIZED TRIAL OF TENECTEPLASE OR PLACEBO WITH LOW MOLECULAR WEIGHT HEPARIN FOR ACUTE SUBMASSIVE PULMONARY EMBOLISM: ASSESSMENT OF PATIENT–ORIENTED CARDIOPULMONARY OUTCOMES AT THREE MONTHS

Acute submassive pulmonary embolism (PE) with right ventricular (RV) injury and/or concomitant deep venous thrombosis can cause persistent symptoms that degrade quality of life. We tested the hypothesis that intravenous tenecteplase would improve the probability of a favorable outcome at three

The Incidence, Risk Factors, and Prognosis of Recurrent Venous Thromboembolism (VTE) in Patients with Advanced Solid Cancers Receiving Anticoagulation Therapy After the Diagnosis of Index Vte; A Korean Venous Thromboembolism Registry Study.

AbstractAbstract 2247 IntroductionPatients (pts) with cancer have been associated with increased risk of recurrent venous thromboembolism (VTE). However, few data are available regarding the recurrent VTE in Asian pts with advanced solid cancers. Thus, the aim of the study is to investigate the incidence and risk factors for recurrent VTE in pts with advanced solid cancers receiving anticoagulation therapy after index VTE. And, we also evaluate the prognostic impact of recurrent VTE on overall survival (OS) in this population. MethodsThis study was conducted using data from the web-based registry of the Korean Thrombosis Working Party (http://kdvt.chamc.co.kr), which is an ongoing, multicenter database for recruiting consecutive pts presenting with VTE. Pts were included in the study cohort if they had been diagnosed with recurrent/metastatic solid cancers between May 2004 and Dec 2011 and initiated anticoagulation therapy. Pts were excluded if they had received a diagnosis of hematologic malignancies, if solid cancers were not recurrent or metastatic disease, if index VTE was intra-abdominal venous thrombosis or vascular access-induced thrombosis, or if anticoagulation therapy was not instituted. Pts were also excluded if they were lost to follow-up within 1 week after initiating anticoagulation therapy. Maximal duration of anticoagulation therapy was 12 months and pts in whom anticoagulation therapy was stopped within 12 months were censored at the time of discontinuation. ResultsA total of 456 pts were included in this analysis. The median age was 65 (range, 27–91) years and 249 pts (55%) were male. Eastern Cooperative Oncology Group (ECOG) performance status (PS) was 0 or 1 in 185 pts (41%). The primary sites of tumor were breast in 22 (5%), genito-urinary tracts in 38 (8%), esophago-gastric in 76 (17%), colo-rectum in 81 (18%), hepato-biliary tracts in 37 (8%), pancreas in 66 (15%), and lung in 136 (30%). Palliative chemotherapy was administered in 328 pts (72%). The location of index VTE was isolated pulmonary embolism (PE) in 196 (43%), isolated lower-extremity deep venous thrombosis (DVT) in 169 (37%), and concomitant PE and DVT in 91 (20%). For initial anticoagulation therapy, low molecular weight heparin was administered in 362 pts (79%), and for long-term therapy, 306 pts (75%) received warfarin. The median duration of anticoagulation therapy after index VTE was 2.4 (range, 0.1–58.3) months.The 6-months and 12-month cumulative incidences of recurrent VTE were 22.4% (95% CI, 19.4–25.4) and 28.7% (95% CI, 24.0–33.4), respectively. In the multivariate analysis for identifying the risk factors associated with the development of recurrent VTE, pancreas (HR, 6.12; 95% CI, 2.00–18.73) and lung (HR, 2.98; 95% CI, 1.03–8.58) as the primary tumor site, poor ECOG PS (HR, 1.74; 95% CI, 1.14–2.67) and VTE initially presented with PE (HR, 2.29; 95% CI, 1.17–4.47) were independent risk factors for increased risk of recurrent VTE.With a median follow-up of 29.1 (range, 1.0–91.2) months, median OS was 11.9 (95% CI, 10.2–13.6) months. Pts with recurrent VTE had a significantly shorter OS than those without recurrent VTE (median, 8.4 vs. 13.0 months, P<0.001). In the multivariate model, occurrence of recurrent VTE was independently associated with the increased risk of death (HR, 1.39; 95% CI, 1.03–1.88). ConclusionAlthough Asian populations are thought to have lower risk for developing recurrent VTE, our study demonstrates that the incidence of recurrent VTE in pts with advanced solid cancers is comparable to that of Western populations. Lung or pancreas as a primary tumor site, poor PS, and initial presentation with PE are independent risk factors for recurrent VTE. Additionally, survival is adversely affected by recurrent VTE. Further studies are needed to validate the results of our study and to optimize the treatment strategies for improving treatment outcomes in advanced cancer pts. Disclosures:No relevant conflicts of interest to declare.

Prognostic Significance of Deep Vein Thrombosis in Patients Presenting with Acute Symptomatic Pulmonary Embolism

Conclusion: In patients with an acute symptomatic pulmonary embolism (PE), a concurrent diagnosis of deep venous thrombosis (DVT) is an independent predictor of increased risk of death within 3 months after the PE diagnosis. Summary: The 3-month mortality rates after an objectively confirmed diagnosis of acute PE vary from 1.4% to 17.4%. Variability in mortality likely illustrates differences in the clinical spectrum of patients with PE. Early deaths in patients with PE are secondary to PE-associated complications. Underlying medical problems cause most late deaths (Conget F, et al; Thromb Haemost 2008;100:937-42). Up to 61% of patients with acute PE have concomitant DVT (Bradley MJ, et al; Clin Radiol 1995;50:232-4). The significance of finding DVT and PE at the time of presentation of PE is debated. Some studies note that diagnosis of proximal DVT is an independent predictor of adverse outcome. Other studies have not confirmed these findings (Wicki J, et al; Thromb Haemost 2000;84:548-52 and Girard P et al; Chest 2005;128:1593-600). This study aimed to assess the association between a concurrent diagnosis of DVT and PE on risk of death in patients with a first objectively confirmed diagnosis of acute symptomatic PE. The primary end point of this prospective cohort study of outpatients was all cause mortality, and the secondary outcome was PE-specific death in the first 3 months after the PE diagnosis. PE was diagnosed in 707 patients, and DVT was also diagnosed in 362 (51.2%); 77 patients (10.9%) died during follow-up. Patients with concurrent DVT had increased all-cause mortality (adjusted HR, 2.05; 95% CI, 1.24-3.38, P = .005) and increased PE-specific mortality (adjusted HR 4.25; 95% CI, 1.61-11.25, P = .04). An external validation cohort of 4476 patients with acute PE enrolled in the RIETE registry also determined a concurrent DVT diagnosed at the time of PE was a significant predictor of all-cause (adjusted HR, 1.66; 95% CI, 1.28-2.15; P < .001) and PE-specific mortality (HR, 2.01; 95% CI, 1.18-3.44, P = .01). Comment: These data provide evidence that a first episode of acute symptomatic PE with a concurrent diagnosis of DVT imparts increased risk of all-cause and PE-specific death in the first 3 months after a diagnosis of PE. Although some may argue that a patient with a diagnosed PE does not need investigation for lower extremity DVT because the PE is going to be treated with anticoagulation anyway, the data imply patients with PE should undergo investigation for DVT for prognostic purposes and risk stratification. Such studies may identify patients at high risk of early death who may benefit from more intensive surveillance or aggressive therapy.